Document:

EXHIBIT 10.26

     

    AGREEMENT

     

    Made on this 16 day of April 2007 (“Effective
Date”)

     

    by and between

     

    MEDGENICS
MEDICAL ISRAEL, LTD.

    A company
organized and existing
under the laws of
Israel

    with
offices at 12 HaNapach St. Karmiel, Israel

    (“MMI”)

    

    and

    

    MEDGENICS,
INC.

    A company organized and existing
under the laws of Delaware, USA,

    with
principal place of business
at 8000 Towers
Crescent Dr.

    Suite
1300

    Vienna,
Va. 22182 USA

    (“Medgenics”)

    

    WHEREAS MMI has applied for
funding from the OCS (as defined below) under the Law (as defined below) for an approved budget
for the period commencing on June
1, 2006 and ending May
31, 2007 for the research and development projects titled Biopump: Medical device for preparation of autologous skin
implants (OCS file Numbers 37503 and 37679)(the “Grants”); and

    

    WHEREAS The Grants have been
approved by the research committee of the OCS (the “Approved Programs”) and the parties hereto wish to
enter into a development
and license
agreement, pursuant to the terms and conditions set forth
herein;

    

    NOW THEREFOR the parties
hereto agree as follows:

     

    
      	
              1.

            	
              Definitions

            

    

     

    
      	
              1.1

            	
              “Intellectual Property Rights” shall mean patents, patent applications,
      mask works,
      copyrights, trade secrets, “moral” rights,
      confidential and proprietary information of a technical and business nature and
      know-how. Intellectual Property
      includes, but is
      not limited to,
      designs, inventions, algorithms, processes, recipes, schematics,
      logic diagrams, software, hardware,
      firmware, and technical specifications, whether in documentary or non-documentary
      form.

            

    

     

    
      	
              1.2

            	
              “Technology” - the
      know-how, technology and process and other results developed and that will be
      developed by MMI under
      the Approved Programs supported by the OCS or deriving
      therefrom.

            

    

    
       

      
        	
                l.3

              	
                “Technology IP” – all rights in and to the
      Technology.

              

      

    

    

    
      	
              1.4

            	
              “Law” – the Encouragement of Research and Development
      in Industry Law
      (5744-1984) and the regulations
      rules and procedures
      promulgated pursuant thereto as may be amended from time to
      time.

            

    

     

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    
      	
              1.5

            	
              “Net Sales” - gross amount billed on
      sales by MMI of the products covered by the claims of the
      Background IP, 1ess the following: (i) customary trade, quantity, or cash
      discounts and commissions to non-affiliated brokers or agents to the extent actually
      allowed and taken; (ii) amounts repaid or credited by reason of rejection
      or return; and (iii) to the extent separately stated on purchase orders,
      invoices, or other documents of sale, any taxes or other governmental
      charges levied on the production, sale, transportation, delivery, or use
      of such product which is paid by or on behalf of
      MMI;

            

    

     

    
      	
              l.6

            	
              “OCS” – the Office of Chief Scientist of
      the Ministry of Industry, Trade and
  Labor.

            

    

    

    
      	
              2.

            	
              Ownership of
      Rights

            

    

     

    MMI is
and shall remain the Sole owner of the Technology and Technology IP created in
the course of the Approved Programs supported by the OCS or deriving therefrom
and any utilization of such Technology and Technology IP and the results of the
Approved Programs and any other rights deriving from the Approved Programs or
their execution, is subject to the provisions of the Law.

    
       

    

    
      	
              3.

            	
              License

            

    

    
       

      Subject
to obtaining the required prior approvals from the OCS and compliance with the
provisions of the Law, MMI may grant Medgenics licenses for manufacturing, marketing and
distributing of products incorporating or based on the Technology and/or the
Technology IP.

    

     

    
      	
              4.

            	
              Non-Exclusive License
      to Background IP

            

    

     

    
      	
              4.1

            	
              License
      Grant. Medgenics
      herby grants MMI a non-exclusive, worldwide, non-transferable.
      sub-licensable irrevocable license to use Medgenics’ Intellectual Property
      Rights, as existing at date of application made for financial support from
      the OCS under the Grant or developed or obtained independently by
      Medgenics thereafter, as well as such intellectual property rights
      licensed to Medgenics under the certain License Agreement with Yissum
      dated November 23, 2005 (the “Background IP”), solely to the extent
      demonstrated, to the reasonable satisfaction of Medgenics, as required for
      the performance and execution of the Approved Programs and any research
      and development programs support by the OCS, to be technically
      indispensable for MMI in order to develop and commercialize the products
      based on the Technology and Technology IP (all such
      rights granted herein, the “Non-Exclusive License”). The Background IP and all
      Intellectual Property Rights therein shall remain in the sole ownership
      of' Medgenics.

            

    

    

    
      	
              4.2

            	
              Royalties.
      In consideration for
      the grant of the Non-Exclusive License to MMI, MMI shall pay Medgenics a
      royalty equal to the five percent (5%) of the Net Sales of
      the products based on
      the Background IP.

            

    

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    
      	
              5.

            	
              Undertaking

            

    

    
       

      Each of MMI and Medgenics, recognize that
(i) the Technology and Technology IP was developed with financial support of
the Government of the State of Israel through the OCS under the Law, and that (ii) the Law places strict
restrictions on the transfer of know-how and/or manufacturing right,
making all such transfers subject to the absolute discretion of the
Research Committee of the OCS (the “Research Committee”), acting in accordance with the aims
of the Law, and requiring that any such transfer receive the prior written approval of the
Research Committee. Each of MMI and Medgenics hereby undertake: (i) to observe
strictly the requirements of the Law including those relating to the prohibition on transfer
of know-how and/or production rights,
and those relating to payment royalties; (ii) to notify the OCS in any event of
a procedure taken by or against MMI in respect of a liquidation of MMI, or an
appointment of a trustee, liquidator or receiver for MMI, or similar legal
procedures.

    

    

    
      	
              6.

            	
              Miscellaneous

            

    

    
       

      
        	
                6.1

              	
                Governing
      Law and
      Jurisdiction. This Agreement
      shall be governed by
      and construed according to the laws of the state of
      Israel, without regard
      to the
      conflict of
      laws provisions thereof. All disputes
      hereunder shall be resolved in the
      courts of Israel, sitting in Tel
Aviv-Jaffa.

              

      

    

    

    
      
        	
                6.2

              	
                Entire
      Agreement.
      This Agreement constitutes the entire agreement between the parties relating
      to the subject matter hereof, and supersedes and annuls all
      oral or written representations or agreements, privileges or
      understandings between the
      parties relating to the subject matter
      hereof.

              

      

    

    

    
      	
              6.3

            	
              Amendments. This
      Agreement may only be amended
      or modified by an agreement in writing duly signed by the parties hereto.
      The parties undertake to obtain the approval of the OCS for any
      amendment or modification for which such approval is required under
      the Law.

            

    

    

    
      
        	
                6.4

              	
                Severability.
      If any non material condition,
      term or covenant of this Agreement shall at any time be held to be
      void, invalid or unenforceable by a court of final jurisdiction, then
      such
      condition, covenant or term shall be
      construed as severable and such holding shall attach only to such
      condition, covenant or term and shall not in any way affect or render
      void, invalid or unenforceable
      any other condition, covenant or term of this Agreement, and this
      Agreement shall be carried out as if such void, invalid or unenforceable
      term were not embodied
      herein.

              

      

    

    

    
      	
              6.5

            	
              Waiver.
      The failure at any time of either party to enforce any of the terms or
      conditions or any right or to exercise any option of this
      Agreement, will in no way be construed to be a waiver of such
      terms, conditions, rights or options, or in any way to affect the validity
      of this Agreement.

            

    

    

    
      	
              6.6

            	
              Preamble.
      The preamble
      to this Agreement shall form
      an Integral part
thereof.

            

    

    

    
      	
              6.7

            	
              Headings.
      The headings in this Agreement are inserted only as a matter of
      convenience, and shall
      not be taken into consideration in the interpretation
      of this
Agreement.

            

    

    

    
      	
              6.8  

            	
              Notices.
      Any notice,
      demand, request, consent, approval, declaration, delivery
      or other communication hereunder to be
      made pursuant to the provisions of
      this
      Agreement
      shall be sufficiently given or made if in writing and delivered in
      person with receipt acknowledged, sent by registered or
      credited mail, receipt requested, posted prepaid,
      sent by overnight courier with
      guaranteed next day delivery or sent by telex or facsimile
      to the party to whom
      directed at the respective address
      indicated above or to such other
      address as a party may designate
      in writing
      in accordance with
      the provisioins of this Subsection 6.8. A copy of any notice shall
      be also sent to:

            

    

    Pearl,
Cohen Zedek Latzer LLP

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

     

    7 Shenkar
Street, 2nd Gav-Yam
Building,

    Herzelia,
46733, Israel

    Fax:
972-9-972-8001

    Att:
Attorney Mark Cohen

     

    
      	
              6.9

            	
              Further Assurances. The parties hereto shall take any and all
      actions as may be required to satisfy the terms, goals and intent of this
      Agreement and shall take no actions in contravention of
      thereof.

            

    

    

    
      	
              6.l0

            	
              Counterparts. This Agreement may be executed in any
      number of counterparts, each of whom shall be deemed an original and
      enforceable against the parties actually executing such counterpart, and
      all of which together shall constitute one and the same
      instrument.

            

    

    

    IN WITNESS WHEREOF the parties have
signed this Agreement as of the date first above written.

     

    
      
        
          
            
              
                
                  	
                          MMI,
      LTD.

                        	 
      	
                          MEDGENICS,
      INC.

                        
	 
      	 
      	 
      
	
                          Signature:

                        	
                          /s/
      Andrew L. Pearlman

                        	 
      	
                          Signature:

                        	
                          /s/
      Andrew L. Pearlman

                        
	 
      	 
      	 
      
	
                          Name:
      Dr. Andrew L. Pearlman

                        	 
      	
                          Name:
      Dr. Andrew L. Pearlman

                        
	 
      	 
      	 
      
	
                          Title:
      CEO

                        	 
      	
                          Title:
      President and
CEO

                        

                

              

            

          

        

      

    

     

    
      
         

      

      
        4EXHIBIT
10.28

     

    Agreement for Clinical
Trials

    

    (without
CRO)

    

    This Agreement for Clinical Trials
(without CRO) (hereinafter, this “Agreement”) is made this 18  day of March 2010 by and between Medgenics Medical
Israel, Ltd., a company
organized and existing under the laws of the State of Israel with offices
at Misgav Business Park,
Misgav, Israel (hereinafter - the Company), and The Medical
Research,
Infrastructure, and Health Services Fund of the Tel Aviv Medical Center,
a ____________
organized and existing under the laws of the State of Israel with offices at
_____________________ (hereinafter - the Fund), and Dr. Doron Schwartz, an
individual residing at _________________________, and having Israeli I.D. No.:
5556763-0 (hereinafter - the
Principal Investigator). Each of the Company, the Fund, and the Principal
Investigator may be referred to herein as a “Party” and collectively as the
“Parties”.

     

    Whereas:
-

     

    
      	
              a.

            	
              The
      Company has expressed its interest in managing the Clinical Trial, the
      subject of which is “Safety and Efficacy of Sustained Erythropoietin
      Therapy of Anemia in Chronic Kidney Disease Patients using EPODURE
      Biopump” (hereinafter: the “Trial”), with Company’s code name
      “EPODURE Trial”, bearing protocol No. MG-001-02, a copy of which is
      attached as Appendix
      A hereto
      (hereinafter: the “Trial Protocol”);
and

            

    

     

    
      	
              b.

            	
              The
      Company has warranted that to the best of its knowledge it is either the
      sole owner of, or has license to, the intellectual property rights in the
      Product, as defined below, and the Trial Protocol, and there is no
      prohibition under any law and/or agreement to the Company executing this
      Agreement and performing its obligations hereunder in all material
      respects; and

            

    

     

    
      	
              c.

            	
              The
      Fund and the Principal Investigator have the ability, the facilities and
      the staff to perform the Trial, and the Fund and the Principal
      Investigator have agreed to perform the Trial, without any promise of
      success. The Fund and the Principal Investigator have warranted that there
      is no prohibition under any law and/or agreement to the Fund or the
      Principal Investigator executing this Agreement and performing their
      respective obligations hereunder in all material respects;
    and

            

    

     

    
      	
              d.

            	
              The
      Company has agreed to pay the Fund the consideration, specified in Appendix
      C hereto, for the
      performance of the undertakings of the Principal Investigator and the Fund
      under this Agreement; and

            

    

    

    
      	
              e.

            	
              The
      Company shall not pay the Principal Investigator any consideration, it
      being agreed that the Principal Investigator will conduct the Trial under
      the auspices of the Fund and in consideration of whatever compensation the
      Fund will pay to the Principal Investigator pursuant to a separate
      agreement among them.

            

    

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

     

    NOW, THEREFORE, in
consideration of the Parties’ mutual covenants and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
Parties agree as follows:

     

    
      	
              1.

            	
              Preamble and
      Appendices

            

    

     

    
      	
               
      

            	
              a.

            	
              The
      preamble to this Agreement and the representations contained therein
      constitute an integral part of the
Agreement.

            

    

     

    
      	
               
      

            	
              b.

            	
              The
      appendices appended to this Agreement, as specified hereunder, constitute
      an integral part of the Agreement:
-

            

    

     

    Appendix
A - Trial Protocol

     

    Appendix
B - List of Trial Personnel

     

    Appendix
C - Trial Budget and Schedule of Payments

     

    Appendix
D - Directives of Ministry of Health

     

    
      	
               
      

            	
              c.

            	
              The
      provisions of this Agreement shall prevail - in the event of a
      contradiction or non-compliance - over the provisions of any appendix
      attached to this Agreement or which shall be attached hereto in the
      future, unless said appendix explicitly provides that its provisions shall
      prevail over this Agreement. However, existing and/or future Ministry of
      Health regulations and/or guidelines shall prevail over the provisions of
      this Agreement and/or any appendix provided that said regulations and/or
      guidelines are stricter regarding the Company’s undertakings than the
      Company’s undertakings under this Agreement and/or any
      appendix.

            

    

     

    
      	
              2.

            	
              Definitions

            

    

     

    In this
Agreement, the following terms when capitalized shall have the following
meanings set forth below:

    

    
      
        
          
            	
                    “Ministry
      of Health Approval”

                  	
                    Approval
      of the Director General of the Israeli Ministry of Health, or to whomever
      he/she delegated the authority for this purpose, for the performance of
      the Trial by the Fund according to the National Health
      Regulations.

                  
	 
      	 
      
	
                    “Hospital”

                  	
                    The
      Tel-Aviv Sourasky Medical Center.

                  
	 
      	 
      
	
                    this
      “Agreement”

                  	
                    This
      Agreement and its appendices.

                  
	 
      	 
      
	
                    the
      “Product(s)”

                  	
                    BIOPUMP
      implanted tissue platform for sustained production and delivery of
      erythropoietin
(EPODURE)

                  

          

        

      

    

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

    

    
      
        
          	
                  the
      “Trial”

                	
                  as
      defined in Preamble clause “a”, i.e., the Clinical Trial, which shall be
      performed under this Agreement and the Trial Protocol, as each may be
      modified or updated from time to time subject to the consent of Fund and
      Company in writing and in advance.

                
	 
      	 
      
	
                  the
      “Helsinki Declaration”

                	
                  the
      Declaration containing the recommendations guiding investigators in
      biomedical trials involving human beings, Helsinki 1964, as amended in
      Tokyo 1975, and a draft of which appears in the attachment to the National
      Health Regulations.

                
	 
      	 
      
	
                  “Trial
      Protocol”

                	
                  as
      defined in Preamble clause “a”, and appended hereto as Appendix “A” to
      this Agreement, as may be modified or updated from time to time subject to
      the consent of the Fund and the Company in writing and in
      advance.

                
	 
      	 
      
	
                  the
      “IRB”

                	
                  the
      Internal Review Board appointed pursuant to the National Health
      Regulations, the role of which is to approve any medical experiment on
      human subjects that will be conducted by the Fund.

                
	 
      	 
      
	
                  “Trial
      Personnel”

                	
                  the
      team that shall be employed by the Hospital or the Fund for conducting the
      Trial, including the Principal Investigator.

                
	 
      	 
      
	
                  “Participants
      in the Trial”

                	
                  A
      group of persons chosen by the Principal Investigator according to
      criteria established in the Trial Protocol.

                
	 
      	 
      
	
                  “GCP”

                	
                  Ethical
      and scientific quality standards for designing, conducting, recording, and
      reporting trials that involve the participation of human subjects, as
      customized by the Fund.

                
	 
      	 
      
	
                  “National
      Health Regulations”

                	
                  National
      Health Regulations (Medical Trials on Humans),
  5741-1980.

                

        

      

    

      

    
      	
              3.

            	
              The
      Engagement

            

    

     

    
      	
               
      

            	
              3.1

            	
              Upon
      signing this Agreement, the Company appoints the Fund and the Principal
      Investigator, and those two parties undertake, each of them pursuant to
      its authority and share, to perform the Trial according to the stages
      thereof, within the framework and by means of the Hospital and to provide
      all needed facilities, materials and services necessary to complete the
      Trial, while complying with the schedule, the Trial budget and the Trial
      Protocol in Appendix “A”, and while complying with the demands and terms
      established by the Ministry of Health, and all pursuant to the terms and
      conditions of this Agreement. The Fund shall be responsible for and obtain
      all approvals required under any applicable law for the conduct of the
      Trial.

            

    

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

     

    
      	
               
      

            	
              3.2

            	
              Notwithstanding
      sub-section 3.1 above, in the event that the employer-employee
      relationship between the Principal Investigator and the Hospital and/or
      the Fund is terminated for any reason and/or in the event the Principal
      Investigator goes on leave and/or is unable and/or unwilling to carry out
      his duties under this Agreement, for any reason, the Fund may appoint a
      substitute Principal Investigator in place of the Principal Investigator
      subject to the prior written approval of the Company, which shall not
      unreasonably be withheld.

            

    

     

    
      	
              4.

            	
              The
      Term of the Agreement

            

    

     

    
      	
               
      

            	
              4.1

            	
              Subject
      to the terms of this Agreement, the Term of the Agreement shall be the
      duration of the Trial as defined in the Trial Protocol, which shall
      commence on                                
      and end upon completion of the Trial; provided, however, that the rights
      and obligations under Sections 5.6, 6, 8, 9, 10, 11, 12 and 15 shall
      survive the termination or expiration of this
  Agreement.

            

    

     

    
      	
               
      

            	
              4.2

            	
              Notwithstanding
      the aforesaid in sub-section 4.1 above, but subject to the provisions that
      survive termination, the Parties may bring this Agreement to an early end
      at any time, in writing, upon the occurrence of one (or more) of the
      following events: -

            

    

     

    
      	
               
      

            	
              4.2.1

            	
              by
      the Company only, at any time at its sole discretion, by way of a written
      notice to the Fund, thirty (30) days in
advance.

            

    

     

    
      	
               
      

            	
              4.2.2

            	
              if
      the Ministry of Health has voided, directly or indirectly, its approval of
      the Trial or has conditioned its approval on conditions, as to which the
      Fund has notified the Company that it does not intend and/or is unable to
      comply with these conditions in whole or in part. In such case the
      Agreement shall be terminated not later than ten (10) days after such
      notice shall have been sent to the
Company.

            

    

     

    
      	
               
      

            	
              4.2.3

            	
              A
      Party breaches this Agreement and does not cure such breach within thirty
      (30) days after having received a notice in writing from the other Party
      demanding a cure of the breach in reasonable detail so that the breaching
      Party is on notice of the nature of the
breach.

            

    

    

    
      	
               
      

            	
              4.2.4

            	
              A
      party enters into bankruptcy or liquidation proceedings or a receiver is
      appointed over part or all of its assets, and such proceedings are not
      ceased within a period of forty five (45) days from the time that they
      have commenced.

            

    

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

    

    
      	
               
      

            	
              4.2.5

            	
              An
      adverse effect occurs to the Participants in the Trial, which, in the
      absolute discretion of the Fund and/or the Principal Investigator and/or
      the IRB, jeopardizes the safety of the Participants in the Trial and/or
      the Trial Personnel, and prior notice thereof is given immediately to the
      Company by any member of the Trial Personnel and the Principal
      Investigator within a reasonable time from the discovery of such adverse
      effect. In such case the Agreement shall be terminated immediately after
      such notice shall be sent.

            

    

     

    For the
removal of any doubt, it is agreed that the Principal Investigator may not
terminate this Agreement under this section.

     

    
      	
               
      

            	
              4.3

            	
              For
      the avoidance of any doubt, the termination of this Agreement, for any
      reason, shall not prejudice the Company’s undertaking to pay the Fund for
      all services and expenditures of the Fund under this Agreement until the
      termination of the Agreement.

            

    

     

    
      	
              5.

            	
              The
  Trial

            

    

     

    
      	
               
      

            	
              5.1

            	
              The
      Company shall supply to the Principal Investigator the Products and/or
      parts of the Product and/or the materials from which the Product is
      composed, without consideration, at the necessary pharmaceutical standard,
      all in accordance with the schedule and in the quantities provided in the
      Trial Protocol.

            

    

     

    
      	
               
      

            	
              5.2

            	
              The
      Trial shall be performed and managed by the Principal Investigator at the
      Hospital facilities, while making use of the Hospital’s resources, without
      payment of further consideration by the Company
  therefore.

            

    

     

    
      	
               
      

            	
              5.3

            	
              The
      Principal Investigator shall carry out the Trial in accordance with the
      Trial Protocol, GCP, and all the relevant laws and regulations prevailing
      in Israel and in accordance with all necessary permits and/or licenses
      from the relevant authorities.

            

    

     

    
      	
               
      

            	
              5.4

            	
              In
      performance of the Trial, the Fund shall employ, directly or indirectly,
      the Trial Personnel, which will comprise the individuals specified in the
      list appended herewith and marked as Appendix B to this Agreement. In the
      event that any of the Trial Personnel so identified cease to be available
      for the Trial, the Fund will use its best efforts to procure within 30
      days a substitute of a suitably qualified person acceptable to the
      Company. The Fund and the Principal Investigator represent and warrant
      that none of the Trial personnel has been debarred, disqualified or banned
      from conducting clinical studies by any regulatory agency, including the
      Israeli Ministry of Health and the U.S. Food & Drug Administration. In
      the event that prior to or during the Trial, the Fund or the Principal
      Investigator become aware that any of the Trial Personnel becomes
      disbarred, or is in the process of disbarment, the Fund will immediately
      notify the Company in writing and the Fund will procure within 30 days a
      substitute of a suitably qualified person acceptable to the
      Company.

            

    

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

    

    
      	
               
      

            	
              5.5

            	
              Subject
      to the provisions of sub-section 11 below, the representatives of the
      Company shall have the right to examine the results, notes and other
      documents and representations obtained during the course of the Trial,
      during regular working hours and confidentially inspect the Principal
      Investigator’s and the Hospital’s facilities required for performance of
      the Trial, after providing advanced written notice and at a reasonable
      time.

            

    

     

    To avoid
any doubt, it is clarified that this sub-section and any provision of this
Agreement shall not be deemed as providing management and/or supervision
authority to the Company or to anyone on its behalf over the Trial and/or the
Principal Investigator and/or whomever of the Trial Personnel.

     

    
      	
               
      

            	
              5.6

            	
              In
      performance of the Trial, pursuant to this Agreement, the Company
      undertakes to continue to supply the Product to the Fund and/or the
      Hospital, without consideration, in order to complete the commenced
      treatment of the Participants of the Trial at the Principal Investigator’s
      sole and reasonable discretion, or as part of the Trial Protocol, should
      one of the Participants of the Trial become dependent on the
      Product.

            

    

     

    To avoid
any doubt, it is hereby clarified that this obligation of the Company shall
remain in effect even in the event that the Agreement has been terminated or is
voided for any reason, but only for so long as it shall be required under the
guidelines of the Ministry of Health.

     

    
      	
               
      

            	
              5.7

            	
              Notwithstanding
      the Company’s undertakings under this Agreement, the Company undertakes to
      abide by all the relevant laws and regulations prevailing in Israel and in
      accordance with and after all necessary permits and/or licenses from the
      relevant authorities, as are presented to it by the
  Fund.

            

    

    

    
      	
              6.

            	
              Reporting and
      Follow-Up

            

    

     

    
      	
               
      

            	
              6.1

            	
              The
      Principal Investigator shall meet with the representatives of the Company,
      during the customary working hours and to a reasonable extent, in order to
      report to the Company, on an ongoing and consecutive basis, and in order
      to update the Company in all matters related to the performance of the
      Trial, its progress, difficulties, solutions, etc. The Principal
      Investigator shall promptly advise the Company of any serious adverse
      event or unanticipated effect occurring during the Trial, or subsequent to
      the completion or termination of the Study, that becomes known to
      him.

            

    

     

    
      	
               
      

            	
              6.2

            	
              The
      Principal Investigator shall prepare and maintain reasonably complete and
      accurate written records, accounts, notes, report and data of the Trial,
      including case report forms. The Principal Investigator shall prepare the
      case reports forms (CRF) legibly and accurately (or ensure that a
      co-Investigator does so) throughout the Trial, and shall make the CRF
      available to the Company. The Principal Investigator will retain or will
      cause the Fund to retain all such materials and data that the Fund has to
      retain under any applicable law for such periods as such law
      determines.

            

    

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

     

    
      	
               
      

            	
              6.3

            	
              The
      Principal Investigator hereby undertakes to adhere to the accuracy of the
      Trial results as required by the Helsinki Declaration and the
      GCP.

            

    

     

    
      	
              7.

            	
              Financing of the
      Trial

            

    

     

    
      	
               
      

            	
              7.1

            	
              In
      consideration for the performance of the Trial under this Agreement, the
      Company shall pay the Fund the consideration specified in Appendix C to
      this Agreement on the dates specified in Appendix C. Such payments shall
      be made against a proper invoice render a reasonable time in advance of
      the due date for the payment.

            

    

     

    
      	
               
      

            	
              7.2

            	
              To
      avoid any doubt, it is hereby clarified that the Fund and/or the Principal
      Investigator shall not perform any acts which deviate from the acts
      specified in the Trial Protocol and/or are specifically mentioned in this
      Agreement unless the Fund and the Company have both approved said acts, in
      advance and in writing.

            

    

     

    
      	
              8.

            	
              Insurance
      and Indemnity

            

    

     

    
      	
               
      

            	
              8.1

            	
              The
      Company shall indemnify and hold harmless the Hospital, the Fund, the
      Principal Investigator, the Trial Personnel and all other employees of the
      Hospital and the Fund (hereinafter: the “Indemnitees”) from and against
      any loss, damage, liability and expense (including legal costs) arising
      out of or resulting, directly or indirectly, from the use of the Products
      and/or any other materials which have been supplied by the Company and/or
      from conducting the Trial in accordance with the Trial Protocol, except to
      the extent that such loss, damage, liability or expense are a result of
      the negligent acts, willfulness, misconduct or breach of contract of any
      of the Fund, the Principal Investigator or the Trial
      Personnel.

            

    

    

    This
indemnity is subject to the following conditions:

     

    
      	
               
      

            	
              8.1.1

            	
              The
      indemnity shall not apply in case of claims or losses arising from a
      breach of the Trial Protocol, GCP, Helsinki Declaration, National Health
      Regulations, and/or any other applicable law or regulation relating to the
      Trial.

            

    

     

    
      	
               
      

            	
              8.1.2

            	
              The
      Company will be notified promptly and in writing of any complaint or claim
      promptly after the Fund becomes aware of the
  same.

            

    

     

    
      	
               
      

            	
              8.1.3

            	
              The
      Company will be given absolute and sole discretion in the defense and
      settlement of any such complaint or
claim.

            

    

     

    
      	
               
      

            	
              8.1.4

            	
              The
      Fund shall cooperate with and give the Company reasonable assistance in
      connection with any such claim or proceedings at Company’s cost and
      expense, and shall consent to any reasonable settlement of such complaint
      or claim approved by the Company.

            

    

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

     

    
      	
               
      

            	
              8.2

            	
              Without
      derogation from Company’s liability under this Agreement and/or under any
      applicable law, including the Ministry of Health Directive, Company
      undertakes to present the Fund an Insurance Certificate according to the
      law of Israel and the Guidelines of the Ministry of Health. The
      Certificate will specifically include the following
      provisions:

            

    

    

    Type of
insurance – one of the followings:

     

    No Fault
Insurance for Clinical Trial with a specific sub-limit for not less than
$3,000,000 any one Occurrence and in the aggregate;

    or

     

    Liability
Insurance including coverage for Clinical Trials with a specific sub-limit for
not less than $3,000,000 any one Occurrence and in the aggregate.

    

    The
policy shall include as additional insured the Fund, the Tel Aviv Sourasky
Medical Centre and/or their employees and/or the Principal Investigator and/or
Sub Investigators and/or the Ethics Committee and/or any medical personnel
involved in performing the Clinical Trial.

    

    The
insurance coverage shall be in force until the Trail and the discovery period
shall be of 7 years.

    

    
      	
               
      

            	
              8.5.

            	
              The
      Company hereby undertakes that any and all settlements of indemnification
      claims hereunder by the Company and/or its insurers will be free of
      admission of any liability whatsoever on the part of the
      Indemnitees.

            

    

     

    
      	
               
      

            	
              8.6.

            	
              The
      Company’s undertaking under this section shall survive termination of this
      Agreement for whatever reason.

            

    

     

    
      	
              9.

            	
              Limitation of Liability.
      The Parties agree that the Parties shall be liable for direct
      damages only and that no Party shall be liable for indirect, incidental or
      consequential damages in connection with the
  Agreement.

            

    

    

    
      	
              10.

            	
              Intellectual
      Property

            

    

    

    All
rights and title to and/or interests in the data, information, conceptions, and
results derived from the Trial and/or the Product as well as any inventions or
discoveries invented, patent applications, or discovered in connection
therewith, including without limitation, any materials, compositions, treatments
or methods which may be developed based thereon (hereinafter, collectively the
“IP”) are and shall be owned by and are and will be the sole and exclusive
property of the Company.

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

    

    The Fund
and the Principal Investigator hereby assign and transfer and shall make efforts
to cause all Trial Personnel to assign and transfer to the Company all right,
title and interest to the IP and to any invention or other proprietary rights
relating to or deriving from the conduct of the Trial which are conceived,
reduced into practice or developed by them under or as a result of this
Agreement or the performance of the Trial and agree to take all further acts
reasonably required, at the Company’s expense, to convey title in such IP or
other proprietary rights to the Company and/or to assist the Company, at the
Company’s cost and expense, to perfect and protect such rights including by way
of preparation, filing, and prosecution of any patent application, copyrights,
or other rights on such proprietary rights and to maintain the same in any and
all countries.

    

    
      	
              11.

            	
              Exploitation of the Trial
      Results

            

    

     

    It is
hereby agreed that the Company has and shall have the sole and absolute right,
without limitation of time or place, worldwide (i.e., in Israel or abroad),
subject only to limitations under the law and the regulations of the Ministry of
Health, to make any and all uses of the IP, including without limitation to
manufacture and/or market and/or sell and/or grant a right of use in the
production and/or marketing rights of the Product and/or accompanying products
which shall derive from the Trial, directly or indirectly, and rights to perform
research and development on said IP, including any modifications and/or
improvements of the same.

     

    The Fund,
the Principal Investigator, the Trial Personnel and all other employees of the
Fund involved in conducting the Trial shall not have any claim or demand against
the Company for any payment, royalties or compensation of whatever type deriving
from the development or sale of any such medicine, medical devices, treatments
or methods or any other rights pertaining to the data, information and/or
results derived from conducting the Trial.

    

    
      	
              12.

            	
              Confidentiality

            

    

     

    
      	
               
      

            	
              12.1

            	
              The
      Fund and the Principal Investigator undertake to keep, and shall cause all
      other Trial Personnel to keep, in absolute confidence, not to transfer or
      disclose to any person and/or entity and not to make any use, other than
      for purposes of the performance of the Trial, any information, data,
      inventions, conceptions, results, or know-how, whether orally or in
      writing, which shall come into their possession in relation to and/or in
      connection with the Trial, the Trial Results and/or the Product and/or the
      IP (hereinafter - the Confidential
Information).

            

    

     

    
      	
               
      

            	
              12.2

            	
              It
      is hereby clarified that submission of the Confidential Information
      pursuant to the demands of the authorities operating by virtue of the law
      and according to their authority, after prior written notice has been
      delivered with respect to same to the Company, as well as the exposure of
      Confidential Information, after it has become public domain, but not as a
      result of its being published in a patent application or granted patent,
      and not as a result of the acts and omissions of the Hospital, the Fund,
      the Principal Investigator and/or any other Trial Personnel, shall not be
      considered a breach of this
Agreement.

            

    

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

    

    
      	
               
      

            	
              12.3

            	
              At
      the request of the Company, the Principal Investigator or the Fund, as the
      case may be, will return to the Company all copies or other manifestations
      of Confidential Information that may be in the possession of the Principal
      Investigator or the Fund, except for materials that have to be retained by
      the Principal Investigator or the Fund in accordance with applicable
      law.

            

    

     

    
      	
              13.

            	
              Publications

            

    

     

    
      	
               
      

            	
              13.1

            	
              The
      Principal Investigator and the Fund hereby undertake to submit to the
      Company all drafts of any publications proposed for publication by the
      Principal Investigator, no later than sixty (60) days prior to the
      submission of any form of such publication or drafts thereof to any
      journal, publisher, and/or any other third
  party.

            

    

     

    
      	
               
      

            	
              13.2

            	
              The
      Company hereby undertakes to promptly inform the Principal Investigator
      and the Fund of any changes and/or deletions the Principal Investigator is
      to perform in such publications, required for the purpose of preserving
      the confidentiality and proprietary rights of the Company under this
      Agreement. It is agreed that the Principal Investigator and/or the Fund
      shall not make any publication of information to which the Company objects
      under this sub-section 12.2.

            

    

     

    
      	
               
      

            	
              13.3

            	
              Without
      derogating from the above, the Company hereby undertakes to abide by the
      rules of publications issued by the Ministry of Health including and
      without limitation the Guidelines for the Conduct of Clinical Trials in
      Human Subjects issued by the Israeli Ministry of Health in 2006, or any
      guidelines issued in addition thereto or in substitution
      thereof.

            

    

     

    
      	
               
      

            	
              13.4

            	
              As
      a condition for performing the Trial, the Company shall be responsible for
      publishing the Trial in the NIH web sites in accordance with the
      instructions of the General Manager of the Israeli Ministry of Health
      published in 4/9/05.

            

    

     

    
      	
              14.

            	
              Relations of the
      Parties

            

    

     

    This
Agreement shall not create relations of agency and/or partnership and/or
employer-employee relations between the Company and the Fund and/or Hospital
and/or the Principal Investigator and/or the Trial Personnel.

    

    
      	
              15.

            	
              Suspending
      Conditions

            

    

     

    The
Parties hereby agree and undertake that the Agreement shall not enter into
effect before the three (3) following cumulative approvals shall have been
granted with regard to the Trial; provided, however, that the rights and
obligations provided in Section 11 above shall be effective from the date of
execution of this Agreement:

     

    
      	
               
      

            	
              15.1

            	
              Approval
      of the Trial Protocol by the IRB and/or by the Ministry of Health, if
      required by the National Health
Regulations.

            

    

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

    

    The
Principal Investigator shall submit the Trial Protocol to the IRB to obtain
approval for conducting the Trial and/or to the Ministry of Health, if required
by the National Health Regulations.

     

    
      	
               
      

            	
              15.2

            	
              Approval
      of this Agreement in general and its Budget by the Ministry of Health and
      specifically by the Contracting Committee of the Ministry of
      Health.

            

    

     

    
      	
               
      

            	
              15.3

            	
              Pursuant
      to section 8.5 of this Agreement, a written Confirmation of Insurance
      shall be provided to the Fund.

            

    

     

    
      	
              16.

            	
              Governing Law and
      Jurisdiction

            

    

     

    
      	
               
      

            	
              16.1

            	
              This
      Agreement shall be exclusively governed by the Laws of the State of
      Israel.

            

    

     

    
      	
               
      

            	
              16.2

            	
              Any
      dispute, controversy or claim arising under, out of or relating to this
      Agreement (and subsequent amendments thereof), its validity, binding
      effect, interpretation, performance, breach or termination, including tort
      claims, shall be exclusively referred to the competent courts in Tel Aviv,
      Israel.

            

    

     

    
      	
              17.

            	
              Non-Waiver of
      Rights

            

    

     

    A Party
to this Agreement shall not be considered as waiving its rights which it has
acquired pursuant to the same and by virtue thereof because it has failed to
ensure the immediate enforcement of any right or because it has granted another
Party an extension or delay, and a waiver or extension granted in one case shall
not be considered or regarded as a waiver or extension in another, whether in
the same matter or in another matter.

    

    
      	
              18.

            	
              Endorsement, Assignment and
      Transfer

            

    

     

    A Party
to this Agreement shall not transfer, endorse or assign its debts, obligations
or rights pursuant to and by virtue of this Agreement, or a part thereof (each,
an “Assignment”), all as the case may be (hereinafter - the Transferor) to any
third party, unless the prior written consent of the other Parties has been
obtained. Notwithstanding the foregoing, the Fund shall not, without reasonable
ground, withhold its consent to any Assignment by the Company if such Assignment
is being made (a) to any entity that acquires fifty percent (50%) or more of
that Company’s shares or voting securities or all or substantially all of its
assets, or (b) as part of a reorganization, re-incorporation or merger of the
Company. Subject to the foregoing, this Agreement will benefit and bind the
parties’ successors and assigns.

    

    
      	
              19.

            	
              Cooperation between the
      Parties

            

    

     

    The
Parties shall take all actions necessary to execute the provisions of this
Agreement, and shall cause that at each one of them all the decisions required
by this Agreement will be made and all the acts performed. The Parties shall
cooperate with each other and shall act in good faith in all things relating to
their engagement in this Agreement and all matters derived
therefrom.

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

    

    
      	
              20.

            	
              Force
      Majeure

            

    

     

    
      	
               
      

            	
              20.1

            	
              Notwithstanding
      the aforesaid in this Agreement, a delay in the performance of an
      obligation imposed on any Party due to an event which falls under the
      definition of the term “Force Majeure” shall not be considered a breach of
      the Agreement, and performance of the said obligation shall be deferred
      until a date when the hindrance is removed, whereas the schedule will be
      amended accordingly, unless the performance has become, due to the delay,
      unreasonable under the circumstance of the
  matter.

            

    

     

    
      	
               
      

            	
              20.2

            	
              For
      purposes of this Agreement, the term “Force Majeure” shall mean acts of
      war, acts of terror, sabotage, general conscription, decisions of legal
      tribunals (including injunctions, whether temporary or permanent), the
      acts and omissions of an authority operating pursuant to law, statute,
      strikes, state of emergency at the Hospital, and general stoppage of the
      economy, natural disasters and other events that are not under the
      reasonable control of the Party alleging the occurrence of the “Force
      Majeure” event if that same Party alleging the occurrence of the said
      “Force Majeure” event has taken all reasonable measures to prevent their
      occurrence and/or continuance.

            

    

     

    
      	
              21.

            	
              Interpretation

            

    

     

    
      	
               
      

            	
              21.1

            	
              Any
      change or addition to this Agreement shall be made in writing and with the
      signatures of all of the Parties affected by said change or addition
      only.

            

    

     

    
      	
               
      

            	
              21.2

            	
              In
      the event it is determined that any provision of this Agreement - which
      does not constitute a material and basic term herein - is invalid, illegal
      or unenforceable, this will be insufficient to cause the avoidance of the
      rest of the provisions of this Agreement and/or to affect the validity,
      legality or the possibility of the enforcement of the rest of the
      provisions, as stated.

            

    

     

    
      	
               
      

            	
              21.3

            	
              This
      Agreement shall replace any prior binder, representation, engagement,
      arrangement or agreement between the parties, the subject matter of which
      is the Trial, and voids them to the extent that they
  exist.

            

    

     

    
      	
              22.

            	
              Notice and
      Addresses

            

    

    

    
      	
               
      

            	
              22.1

            	
              The
      addresses of the Parties for purposes of this Agreement shall be:
      -

            

    

    

    The
Company – Misgav Business Par, P.O. Box 14, Misgav 20179

    

    The Fund
- 6 Weizmann Street, Tel-Aviv

    

    The
Principal Investigator – at the Fund.

     

    
      	
               
      

            	
              22.2

            	
              A
      Party who shall change its address will submit notice of the same within a
      reasonable time to the other
Parties.

            

    

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

    

    
      	
               
      

            	
              22.3

            	
              A
      notice that must be submitted pursuant to this Agreement will be delivered
      to the Parties at the addresses specified above, by personal
      delivery.

            

    

     

    
      	
               
      

            	
              22.4

            	
              Any
      notice submitted in accordance with this section shall be considered as if
      delivered to its address after the passing of one business day from the
      date on which receipt has been
confirmed.

            

    

    

    In
witness whereof the parties set their hands

     

    on
the date and at the location set forth above: -

    

    
      
        
          
            
              	
                      /s/
      Andrew L. Pearlman

                    	 
      	
                      /s/
      Raz Tabib
Raz Tabib

                      General Manager

                      Research & Development Fund

                      Tel-Aviv Sourasky Medical Center

                      Israel

                    	 
      	
                      /s/
      Doron
      Schwartz

                      Doron
      Schwartz,
      MD

                      
                        Tel-Aviv Sourasky Medical Center

                        Israel

                      

                    
	 	 	 	 	 
	
                      The
      Company

                    	
                        

                    	
                      The
      Fund

                    	
                        

                    	
                      The
      Principal
Investigator

                    

            

          

        

      

    

     

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

    

    Appendix
A - Trial Protocol

    

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

    

    Appendix
B - List of Trial Personnel

    

    
      	 	
              1.

            	
              Dr.
      Doron Swartz – Principle
Investigator

            

    

     

    
      	 	
              2.

            	
              Dr.
      Gil Tzarnin – sub Principle
Investigator

            

    

     

    
      	 	
              3.

            	
              Prof.
      Don Silverberg – sub Principle
Investigator

            

    

     

    
      	 	
              4.

            	
              Ofer
      Rap – Site Study Coordinator

            

    

     

    
      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

    

    

    Appendix
C - Trial Budget and Schedule of Payments

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            	 
      	 	
                                    Ichilov
      Budget

                                  	 
	
                                    Itemized per patient fees:

                                  	 	
                                    Quantity

                                  	 	 	
                                    ea.

                                  	 	 	
                                    Total

                                  	 
	
                                    Sub
      Investigator

                                  	 	 	1	 	 	$	2,300	 	 	$	2,300	 
	
                                    Sub
      Investigator

                                  	 	 	1	 	 	$	1,725	 	 	$	1,725	 
	
                                    Sub
      Investigator

                                  	 	 	1	 	 	$	1,725	 	 	$	1,725	 
	
                                    Plastic
      surgeon (per procedure)

                                  	 	 	2	 	 	$	575	 	 	$	1,150	 
	
                                    Operating
      room nurse (per procedure)

                                  	 	 	2	 	 	$	173	 	 	$	345	 
	
                                    Per
      Patient subtotal

                                  	   	 	 	 	 	 	 	 	 	$	7,245	 
	 
      	 	 	 	 	 	 	 	 	 	 	 	 
	
                                    Extended
      follow-up - per month per patient

                                  	 	 	1	 	 	$	575	 	 	$	575	 
	
                                    Screening
      without enrollment (per patient)

                                  	 	 	1	 	 	$	575	 	 	$	575	 
	
                                    Patient
      reimbursement (estimated per patient)

                                  	 	 	 	 	 	$	2,000	 	 	$	2,000	 

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

    

    Notes:

    Central
lab (AML), travel expenses, shipments - are paid directly by Medgenics to the
subcontractors. 

    Patient
travel expenses will be paid to the taxi service directly by
Medgenics.

     

    Payment
Terms:

    

    
      	
               
      

            	
              1.

            	
              On
      receipt of invoice, Net +30 days

            

    

    

    
      	
               
      

            	
              2.

            	
              For
      each patient recruited into the trial, the Company will be
      invoiced:

            

    

    

    
      	
               
      

            	
              a.

            	
              60%
      at patient enrollment

            

    

    

    
      	
               
      

            	
              b.

            	
              40%
      at patient termination (or completion of 6 months of
      follow-up)

            

    

    

    
      	
               
      

            	
              c.

            	
              Extended
      follow-up: invoiced on a quarterly
basis

            

    

    

    
      	
               
      

            	
              d.

            	
              Patient
      reimbursement will be charged to the Company without overhead, invoiced on
      a quarterly basis

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]